Inhibition of receptor-interacting serine/threonine-protein kinase 2 (RIPK2) has been previously described as a promising strategy for the treatment of inflammatory bowel disease, as RIPK2 is a key player in the signaling leading to bacterial peptidoglycan (PGN)-induced inflammation and it amplifies pro-inflammatory responses in the intestine.

Researchers from China Pharmaceutical University have recently reported the discovery and preclinical characterization of a series of novel dihydroquinolin-4(1H)-one derivatives targeting the colchicine-binding site and intended for use as antitumor agents.

Shanghai Henlius Biotech Inc. has announced IND approval by the FDA for HLX-42 for injection, an antibody-drug conjugate (ADC) developed under a collaboration between Henlius and Medilink Therapeutics.

Disrupting apoptosis is a mechanism that cancerous cells use to avoid being killed; this can be performed by overexpressing pro-survival factors, such as induced myeloid leukemia cell differentiation protein Mcl-1. Researchers from Abbvie Inc. have recently published preclinical data on a potent and selective Mcl-1 inhibitor, ABBV-467, for the treatment of hematologic cancers.

A laboratory technique used to generate pluripotent stem cells from any tissue, cellular reprogramming, has led a group of researchers to the discovery of a process that could have an impact on natural tissue repair.